Patents by Inventor V. John Jasys

V. John Jasys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
    Patent number: 6858744
    Abstract: This invention relates to dihydroxyhexanoic acid derivatives and their intermediates, as well as to methods of preparing such compounds. Additionally, present invention relates to removing a protecting group from a protected amine wherein the method comprises reacting the protected amine with phosphoric acid.
    Type: Grant
    Filed: May 7, 2003
    Date of Patent: February 22, 2005
    Assignee: Pfizer Inc.
    Inventors: John C. Kath, Zhengong B. Li, V. John Jasys, Frank J. Urban
  • Dihydro-furan-2-one derivatives, their intermediates and methods of manufacture
    Publication number: 20040049057
    Abstract: This invention relates to dihydro-furan-2-one derivatives, their intermediates and methods of manufacture.
    Type: Application
    Filed: May 7, 2003
    Publication date: March 11, 2004
    Applicant: Pfizer Inc.
    Inventors: Frank J. Urban, V. John Jasys, Zhengong B. Li
  • Dihydoxyhexanoic acid derivatives, their intermediates, and methods of making
    Publication number: 20040019217
    Abstract: This invention relates to dihydroxyhexanoic acid derivatives and their intermediates, as well as to methods of preparing such compounds. Additionally, present invention relates to removing a protecting group from a protected amine wherein the method comprises reacting the protected amine with phosphoric acid.
    Type: Application
    Filed: May 7, 2003
    Publication date: January 29, 2004
    Applicant: Pfizer Inc.
    Inventors: John C. Kath, Zhengong B. Li, V. John Jasys, Frank J. Urban
  • Beta-lactam elastase inhibitors
    Patent number: 5132300
    Abstract: Novel beta lactam compounds having potent elastrase inhibition activity are disclosed. These compounds are characterized by the general structural formulae I, II, and III: ##STR1## These compounds are further characterized such that X and Y are each --S-- or --CH.sub.2 --, with at least one of X and Y being --S--, or alternatively, X is --SO-- or --SO.sub.2 -- and Y is --CH.sub.2 --; R.sup.1 is hydrogen, tri(lower alkyl)silyl, --COOR" or --CONHR"', wherein R" and R"' are each lower alkyl or phenyl(lower alkyl), and may be the same or different; R.sup.3 is hydrogen, lower alkyl or (lower alkyl)oxy; one of B and D is (lower alkyl)oxycarbonyl, (lower alkenyl)oxycarbonyl, allyloxycarbonyl or phenyl(lower alkyl)oxycarbonyl; and the other of B and D is hydrogen or lower alkyl.The compounds are useful as anti-inflammatory agents, particularly in the treatment of adult respiratory distress syndrome and rheumatoid arthritis.
    Type: Grant
    Filed: June 1, 1989
    Date of Patent: July 21, 1992
    Assignee: Pfizer Inc.
    Inventors: Robert A. Volkmann, V. John Jasys, Michael S. Kellogg